Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study.

Bibliographic Details
Title: Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study.
Authors: Yamada, Hirotaka, Jinno, Sadao, Maeda, Toshihisa, Hayashi, Shinya, Yamamoto, Wataru, Onishi, Akira, Onizawa, Hideo, Takeuchi, Tohru, Hiramatsu, Yuri, Okita, Yasutaka, Ebina, Kosuke, Son, Yonsu, Yoshida, Naofumi, Watanabe, Ryu, Hara, Ryota, Yamashita, Mai, Nose, Yoko, Yamamoto, Yuzuru, Okano, Takaichi, Nishimura, Keisuke
Source: Rheumatology; Aug2024, Vol. 63 Issue 8, p2147-2151, 5p
Subject Terms: BIOTHERAPY, CROSS-sectional method, RESEARCH funding, RHEUMATOID arthritis, MULTIPLE regression analysis, SCIENTIFIC observation, SYMPTOMS, DISEASE remission, ANTIRHEUMATIC agents, DESCRIPTIVE statistics, LONGITUDINAL method, RESEARCH, SOCIODEMOGRAPHIC factors, SYNTHETIC drugs, GLUCOCORTICOIDS, OLD age
Geographic Terms: JAPAN
Abstract: Objectives To investigate if disease activity among elderly RA patients >75 years of age has changed over time in the real-world clinical setting. Methods Data from an observational multicentre registry of RA patients in Japan were analysed. The primary outcome was to evaluate the changes in the proportion of very elderly RA patients (>75 years) who achieved remission and low disease activity (LDA), from 2014 to 2021. The secondary outcome was to identify factors associated with remission and LDA by comparing demographic and clinical characteristics among the patients who had a study visit within the study period, using multivariate logistic regression. Results A total of 32 161 patient visits were identified from 2014 to 2021. The proportion of patients >75 years of age increased from 16.5% to 26.9%, with biologics and targeted synthetic DMARDs (b/tsDMARDs) use increasing and glucocorticoids use decreasing, while conventional synthetic DMARDs use remained relatively stable. The proportion of RA patients >75 years of age achieving remission and LDA significantly increased from 62.2% to 78.2% (P for trend < 0.001). A negative factor associated with achieving remission and LDA was glucocorticoid use, seropositivity and a history of previous b/tsDMARDs use while MTX use was associated positively, independent of other predictors. Conclusions In our cohort, disease activity among very elderly RA patients has improved over time. The study suggests the importance of using a treat-to-target approach in very elderly RA patients to improve clinical outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:14620324
DOI:10.1093/rheumatology/kead539
Published in:Rheumatology
Language:English